The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment

Pioneer in uniting imaging technology with radiotherapy to explore potential of
MRI to refine tumor targeting
MANCHESTER, England, July 22, 2014 – Elekta (NSE:EKTAb) and Royal Philips
(NYSE:PHG, AEX:PHIA) announced today that The Christie NHS Foundation Trust
(Manchester, UK), a specialist cancer center, will join a consortium whose
mission is to develop the clinical value of an integrated magnetic resonance
imaging (MRI) guided radiation therapy system. Such a system would, in
principle, improve the practice of radiotherapy via real-time visualization of
cancer targets.

“The Christie was an essential participant in the project 14 years ago that laid
the foundations of the use of cone beam computed tomography [CBCT] at the time
of treatment to improve radiotherapy delivery,” says Niklas Savander, Elekta
President and CEO. “It has a dedicated team of researchers in medical physics,
radiotherapy and clinical oncology and MR imaging that is committed to the most
accurate and individualized delivery of radiation therapy. The Christie has the
perfect blend of experience and expertise to further help the consortium make
MRI-guided radiation therapy a reality.”

The Christie is the seventh member to join the research consortium that assesses
the novel technology, which brings together state-of-the-art radiation therapy
and MRI in a single system. The consortium also includes the University Medical
Center Utrecht (Utrecht, the Netherlands), The University of Texas MD Anderson
Cancer Center (Houston, Texas), The Netherlands Cancer Institute-Antoni van
Leeuwenhoek Hospital (Amsterdam, the Netherlands), Sunnybrook Health Sciences
Centre (Toronto, Ontario), The Froedtert & Medical College of Wisconsin Cancer
Center (Milwaukee, Wisconsin) and The Institute of Cancer Research, working with
its clinical partner The Royal Marsden NHS Foundation Trust (London, England).

“We are very excited to be a part of an international consortium of truly
exceptional centers that are striving as we are to develop technological
innovations to benefit patients,” says Dr. Ananya Choudhury, Consultant and
Honorary Senior Clinical Lecturer, Clinical Oncology at The Christie. “Unlike
any imaging modality now in use in combination with radiotherapy, MRI can
provide highly detailed images of the tumor and surrounding normal tissues.
Moreover, MRI will permit physicians to non-invasively visualize and track the
target during beam delivery – real-time imaging – which will further improve
treatment accuracy.”

The Christie joined the recent research consortium meeting at Utrecht, where the
clinical indications that would benefit the most from the use of MRI-guided
radiation therapy were discussed. These targets are typically going to be in
anatomy that changes its position and shape either from day to day or during the
treatment. The consortium anticipates that the use of MRI imaging at the time of
treatment will result in a considerable increase in the accuracy of the
placement of the dose, reducing the need for large safety margins around the
tumor target.

“When we first started this journey with Elekta and the University Medical
Center Utrecht more than a decade ago, we already had a clear vision, yet we
could only dream of today’s MRI imaging performance,” says Gene Saragnese, CEO
Imaging Systems at Philips Healthcare. “Since then we have come a long way and I
am convinced that with the current state of the technology and the growing
consortium of leaders in radiation therapy delivery, we have the prerequisites
to make the integrated MRI-guided radiation therapy technology a game changer in
cancer care.”

The MRI-guided radiation therapy system is a works in progress and not available
for sale or distribution.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time

Steve Klink, Philips Group Communications
Tel: +31 6 10888824, e-mail: steve.klink@philips.com
Time zone: CET: Central European Time

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on July 22, 2014.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,500 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker STO:EKTAB. Website:
www.elekta.com.

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being
company, focused on improving people’s lives through meaningful innovation in
the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the
Netherlands, Philips posted 2013 sales of EUR 23.3 billion and employs
approximately 112,000 employees with sales and services in more than 100
countries. The company is a leader in cardiac care, acute care and home
healthcare, energy efficient lighting solutions and new lighting applications,
as well as male shaving and grooming and oral healthcare. News from Philips is
located at www.philips.com/newscenter.